Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.35)
# 363
Out of 4,918 analysts
75
Total ratings
57.69%
Success rate
16.71%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $55 | $33.16 | +65.86% | 1 | May 14, 2025 | |
| MRNA Moderna | Maintains: In-Line | $50 → $32 | $27.64 | +15.77% | 6 | May 2, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $190 → $185 | $128.04 | +44.49% | 2 | Apr 24, 2025 | |
| SMMT Summit Therapeutics | Initiates: Outperform | $30 | $29.32 | +2.32% | 1 | Mar 12, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $45 → $50 | $47.75 | +4.71% | 3 | Dec 23, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $45 → $50 | $13.61 | +267.38% | 2 | Dec 17, 2024 | |
| BNTX BioNTech SE | Upgrades: Outperform | $110 → $125 | $110.03 | +13.61% | 4 | Nov 19, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Outperform | $115 → $105 | $60.31 | +74.10% | 12 | Oct 30, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $1,250 → $1,175 | $571.54 | +105.58% | 5 | Oct 24, 2024 | |
| ACLX Arcellx | Initiates: Outperform | $85 | $72.08 | +17.92% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $28.46 | +209.21% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $132.20 | +108.77% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.23 | +727.42% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $301.94 | -23.16% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $78.04 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $114.51 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $26.64 | -21.16% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $3.18 | +623.27% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $310 → $250 | $11.15 | +2,143.16% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.12 | +792.86% | 1 | Feb 14, 2018 |
Xenon Pharmaceuticals
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $33.16
Upside: +65.86%
Moderna
May 2, 2025
Maintains: In-Line
Price Target: $50 → $32
Current: $27.64
Upside: +15.77%
Neurocrine Biosciences
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $128.04
Upside: +44.49%
Summit Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $30
Current: $29.32
Upside: +2.32%
BridgeBio Pharma
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $47.75
Upside: +4.71%
Edgewise Therapeutics
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $13.61
Upside: +267.38%
BioNTech SE
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $110.03
Upside: +13.61%
BioMarin Pharmaceutical
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $60.31
Upside: +74.10%
Regeneron Pharmaceuticals
Oct 24, 2024
Maintains: Outperform
Price Target: $1,250 → $1,175
Current: $571.54
Upside: +105.58%
Arcellx
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $72.08
Upside: +17.92%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $28.46
Upside: +209.21%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $132.20
Upside: +108.77%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.23
Upside: +727.42%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $301.94
Upside: -23.16%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $78.04
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $114.51
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $26.64
Upside: -21.16%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $3.18
Upside: +623.27%
Feb 14, 2018
Maintains: Neutral
Price Target: $310 → $250
Current: $11.15
Upside: +2,143.16%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.12
Upside: +792.86%